| 注册
首页|期刊导航|中国临床药理学杂志|孟鲁司特钠联合特布他林治疗小儿咳嗽变异性哮喘的临床研究

孟鲁司特钠联合特布他林治疗小儿咳嗽变异性哮喘的临床研究

陈建飞 朱乔波 邵东良 纪小艺

中国临床药理学杂志2024,Vol.40Issue(15):2155-2159,5.
中国临床药理学杂志2024,Vol.40Issue(15):2155-2159,5.DOI:10.13699/j.cnki.1001-6821.2024.15.001

孟鲁司特钠联合特布他林治疗小儿咳嗽变异性哮喘的临床研究

Clinical trial of montelukast sodium combined with terbutaline in the treatment of children with cough variant asthma

陈建飞 1朱乔波 1邵东良 1纪小艺1

作者信息

  • 1. 嘉兴市妇幼保健院儿科,浙江嘉兴 314000
  • 折叠

摘要

Abstract

Objective To observe the application effect of montelukast sodium combined with terbutaline on cough variant asthma(CVA)in children and its influence on airway remodeling and peripheral blood inflammatory indicators.Methods The children with CVA were randomly classified into control group and treatment group.The control group was given aerosol inhalation of terbutaline(5 mg each time,twice a day),and on the basis of the control group,the treatment group was combined with oral administration of montelukast sodium granules(4 mg each time,once a day,taking before going to bed),and both groups were continuously treated for 3 months.The clinical efficacy,airway cross-section area(AO),airway lumen area(AI),airway wall thickness(T),airway wall area(WA),serum interleukin-5(IL-5),eosinophilic chemotactic factor(Eotaxin),macrophage inflammatory protein-1α(MIP-1α)and T lymphocyte subgroups CD4+,CD8+and CD4+/CD8+were compared between the two groups of children,and the medication safety was assessed.Results Fifty-three cases in control group and 53 cases in treatment group were included.After treatment,the total effective rates in treatment group and control group were 96.23%(51 cases/53 cases)and 83.02%(44 cases/53 cases),respectively(P<0.05).The AO values in treatment group and control group were(39.42±3.67)and(45.69±4.92)mm2;AI values were(22.36±2.85)and(27.06±3.18)mm2;T values were(1.12±0.28)and(1.44±0.33)mm;WA values were(53.82±4.17)and(60.13±4.66)mm2;serum IL-5 levels were(25.46±5.83)and(41.46±7.64)ng·L-1;Eotaxin levels were(181.24±30.05)and(238.21±39.42)ng·L-1;MIP-1a levels were(15.24±3.67)and(22.43±4.05)ng·L-1;CD4+levels were(37.18±4.06)%and(33.57±3.82)%;CD8+levels were(24.08±3.15)%and(27.31±3.07)%;and CD4+/CD8+levels were 1.54±0.33 and 1.24±0.28,respectively(all P<0.05).The total incidences of adverse drug reactions in treatment group and control group were 9.43%(5 cases/53 cases)and 3.77%(2 cases/53 cases),respectively(P>0.05).Conclusion Montelukast sodium combined with terbutaline has an exact efficacy in the treatment of CVA in children,and it can effectively reverse airway remodeling,reduce inflammation level and enhance immune function,and it has good safety.

关键词

孟鲁司特颗粒/硫酸特布他林雾化吸入用溶液/咳嗽变异性哮喘/气道重塑/炎症因子/安全性评价

Key words

mengdesite granules/terbutaline sulfate aerosol inhalation/cough variant asthma/airway remodeling/inflammatory factor/safety evaluation

分类

药学

引用本文复制引用

陈建飞,朱乔波,邵东良,纪小艺..孟鲁司特钠联合特布他林治疗小儿咳嗽变异性哮喘的临床研究[J].中国临床药理学杂志,2024,40(15):2155-2159,5.

中国临床药理学杂志

OA北大核心CSTPCD

1001-6821

访问量0
|
下载量0
段落导航相关论文